Due to its structure, BAI1 has been considered as a inhibitor of angiogenesis and a candidate for the glioma-derived angiogenesis inhibitory factor (GD-AIF), previously described by Van Meir et al (1994). This evidence concerns the gene ADGRB1 and central nervous system cancer.